Duchenne Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) dropped 2 percent Thursday on news of the FDA’s approval of Marathon Pharmaceuticals' Duchenne Muscular Dystrophy treatment. Emflaza previously secured priority review and orphan drug status, and the FDA green-lighted the product for...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by more than 24 percent Tuesday. The catalyst for the move appears to be the company's 10:30 a.m. presentation at the JPMorgan Healthcare Conference, followed by an encouraging report by TheStreet's Adam Feuerstein. As...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared as high as $63.73 following a controversial decision by the U.S. Food and Drug Administration to approve the company's treatment of Duchenne muscular dystrophy in September 2016. Since the FDA's announcement, the stock has lost more than half...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a biopharmaceutical company that focuses on the treatment of rare diseases, such as Duchenne Muscular Dystrophy (DMD), has become one of the most debated stocks of 2016. After bottoming at $8 per share in early 2016 the stock soared as high as $63.73...

Sarepta Therapeutics Inc (NASDAQ: SRPT) has taken quite a disappointing round-trip for shareholders since the stock jumped from $27.99 to $63.73 in a matter of days back in September. On September 19, the FDA granted accelerated approval for Sarepta’s Exondys 51, which became the first...

After agreeing to cover Sarepta Therapeutics Inc (NASDAQ: SRPT)’s controversial Duchenne muscular dystrophy drug Exondys 51, insurer Aetna Inc (NYSE: AET) has released a new clinical policy bulletin describing the conditions under which it deems the drug medically necessary. Aetna now...

Back on October 6, Duchenne Muscular Dystrophy (DMD) treatment advocate Jenn McNary announced on Twitter that Humana Inc (NYSE: HUM) had approved 100 percent coverage for a patient wanting access to Sarepta Therapeutics Inc (NASDAQ: SRPT) muscular dystrophy drug eteplirsen - marketed as EXONDYS...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared more than 80 percent higher on Friday. The company confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called Translarna (ataluren...

Leerink's Joseph Schwartz felt it prudent to take a deep dive into Sarepta Therapeutics Inc's (NASDAQ: SRPT) EXONDYS 51, the company's therapy for the treatment of Duchenne muscular dystrophy (DMD). There are three reasons investors should take a "more cautious view" on...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared higher by nearly 90 percent early Friday morning after the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) fell about 5 percent Friday after Anthem Blue Cross said the clinical benefit of treatment for DMD (Duchenne Muscular Dystrophy) with the company's eteplirsen (Exondys 51), including improved motor function, has "not been demonstrated....

Sarepta Therapeutics Inc (NASDAQ: SRPT) and Summit Therapeutics plc (NASDAQ: SMMT) reached an exclusive license and collaboration agreement. As a result, Sarepta has been granted rights in Europe, and Turkey apart from the Commonwealth of Independent States to Summit's utrophin modulator...

Sarepta Therapeutics Inc (NASDAQ: SRPT) revealed that it dosed first patient in final stage clinical study of SRP-4045 and SRP-4053 for treatment of Duchenne Muscular Dystrophy Amenable to exon 45 or 53 skipping. The company indicated the third stage trial, ESSENCE, is a double-blind, placebo-...

It looks like Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Eteplirsen may not be out of the woods just yet.  A letter from U.S. Food & Drug Administration Commissioner Robert Califf is calling for the drug's latest study to be retracted. The 13-page memo is dated Friday,...

The craze for Sarepta Therapeutics Inc (NASDAQ: SRPT) shares continued into its second day, gaining about 15 percent on Tuesday. The stock nearly doubled from the $28.15 recorded on September 16. Two catalysts likely responsible for this rally include the FDA approval for the company's Duchenne...